Dilazep, an antiplatelet agent, is generally used as an anti-induced by TNF, suggesting that dilazep blocks the TF expression induced by PMA or thrombin at a transcriptional thrombotic drug in clinical practice. Dilazep is also known to exert cytoprotective and antioxidant effects on endothelial level and that induced by TNF at a posttranscriptional level. Western blot analysis showed that dilazep reduces the accu-cells. However, its effect on the endothelial or monocyte procoagulant activity is unknown. In the current study, the mulation of native TF but increases that in lower molecular weight TF derivatives. The adenosine receptor antagonist, effect of dilazep on the expression of tissue factor (TF) in human umbilical vein endothelial cells (HUVECs) after the 8-(p-sulfophenyl) theophylline, partially counteracted the anticoagulant activity of dilazep on HUVECs, thereby sug-stimulation with tumor necrosis factor-a (TNF), thrombin, or phorbol 12-myristate 13-acetate (PMA) was evaluated. We gesting that the inhibitory effect of dilazep on TF expression in HUVECs depends, at least in part, on its adenosine po-also evaluated the effect of dilazep on TNF (1,000 U/mL)induced TF expression on monocytes. Dilazep inhibited TF tentiating activity. Dilazep also inhibited TNF-induced TF expression on monocytes in a dose-dependent fashion (0.1 to activity induced on HUVECs by each stimulant, TNF (1000 U/mL), thrombin (25 nmol/L), or PMA (5 nmol/L) in a dose-100 mg/mL). In brief, the current study showed for the first time that dilazep, a commonly used antiplatelet drug, dependent fashion (1 to 100 mg/mL). TF activity decreased to approximately 10% after treating with 100 mg/mL of dilazep. strongly inhibits the TF expression in HUVECs and monocytes. Dilazep may have a potent therapeutic value in pa-Dilazep also blocked the expression of TF antigen induced by each stimulant on the surface of HUVECs as determined tients with hypercoagulable state for its inhibitory property on the procoagulant activity of endothelial cells and mono-by flow cytometric analysis. In addition, in HUVECs, it significantly decreased the expression of TF mRNA and the cytes. ᭧ 1997 by The American Society of Hematology. total TF antigen induced by thrombin or PMA, but not those From the Department of Molecular Pathobiology and the Second in patients with ischemic heart disease, cerebral ischemic,
T sion in HUVECs at both transcriptional and posttranscriptional levels, and that its anticoagulant activity depends, in ISSUE FACTOR (TF) is a membrane-bound glycoprotein that activates blood coagulation via the extrinsic clotting pathway. 1 Abnormal expression of TF on endothelial part, on the stimulation of adenosine receptors. cells, monocytes, macrophages, and other intravascular cells may be associated with the occurrence of coronary disease,
MATERIALS AND METHODS

strokes, and arterial or venous thrombosis. 2-4 Upregulation
Materials. Citrated human plasma was obtained from the local of TF on endothelial cells is induced in vitro by cytokines Red Cross blood center. Human factor VIIa and factor X were (tumor necrosis factor-a [TNF] and interleukin-1 [IL-1]), provided by Dr Tomohiro Nakagaki (Chemo-Sera Therapeutic Instimitogens (tumor-promoting phorbol esters such as phorbol tute, Kumamoto, Japan). Antithrombin, 19 protein C, 20 and thrombin 21 12-myristate 13-acetate [PMA]), thrombin, and endotoxin. [5] [6] [7] were prepared from human plasma as described. Recombinant human TNF was donated by the Asahi Chemical Industry (Fuji, Downregulation of TF expression on endothelial cells can Shizuoka, Japan). The synthetic peptide substrate for factor Xa, Nbe induced by various anti-inflammatory cytokines (IL-4, benzoyl-L-isoleucyl-L-glutamyl-glycyl-L-arginine-p-nitroanilide IL-10, and IL-13), retinoic acid, and antioxidants. [8] [9] [10] [11] Antihydrochloride (S2222), was purchased from Chromogenix (Mölndal, platelet agents of the prostanoid family have also been shown Sweden). The fluorogenic substrate for activated protein C, Bocto inhibit the procoagulant activity of endothelial cells by Leu-Ser-Thr-Arg-methylcoumarylamide (MCA), was obtained from increasing the intracellular concentration of cAMP. 12 the Protein Research Foundation (Osaka, Japan). Dulbecco's phos-Dilazep, an antiplatelet agent widely used in European phate-buffered saline (PBS), gentamycin, bovine serum albumin countries and Japan, exerts its antiplatelet activity by increas-(BSA), heparin (174 U/mg), and adenosine were from Sigma (St ing the adenosine levels in the extracellular space fluid. 13, 14 Dilazep is also known to have a vasodilating activity on coronary, cerebral, and renal vessels, 15, 16 and it is often used Louis, MO). Nick column was obtained from Pharmacia-LKB (Upp-after incubating for 20 minutes at room temperature. The reaction was stopped by the addition of 10 mL of 20% acetic acid, and color sala, Sweden). Triton X-100 and aprotinin were from Boehringer Mannheim GmbH (Mannheim, Germany). Glyceraldehyde-3 phos-development was determined by measuring the absorbance at 405 nm with an EAR 340 microplate reader (SLT-Lab Instruments, Salzburg, phate dehydrogenase (GAPDH) cDNA probe and 8-(p-sulfophenyl) theophylline (8-SPT) was purchased from Clontech Labs (Palo Alto, Austria). Flow cytometric analysis of HUVEC surface TF antigen. HU-CA) and Research Biochemicals International (Natick, MA), respectively. Horseradish peroxidase (HRP)-conjugated antimouse IgG-VECs were incubated with or without TNF, thrombin, or PMA in the presence or absence of dilazep for 5 hours and harvested using goat antibody and antigoat IgG-rabbit antibody were obtained from Bio-Rad (Richmond, CA). The reagents to check the viability of the trypsin. The cells were then washed with cold Dulbecco's PBS and resuspended (2 1 10 6 cells) in 100 mL PBS. The cells were incubated cells, WST-1 [2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl )-2H-tetrazolium-Na] and 1-methoxy PMS (1-methoxy-5-with mouse monoclonal antihuman TF IgG (5 mg/mL) 23 for 30 minutes at 4ЊC and subsequently washed three times with PBS. The methyl-phenazinium methylsulphate), were purchased from Dojindo (Kumamoto, Japan).
cells were then incubated with the F(ab) 2 fraction of a fluorescein isothiocyanate (FITC)-labeled antimouse IgG-goat antibody (1/20 Patients. Twenty inoperable patients with malignant disease (adenocarcinoma, 12; squamous cell carcinoma, 2; small-cell carci-dilution) for 30 minutes at 4ЊC. The cells were then washed three times with PBS and fixed in fluorescence-activated cell sorting noma, 2; hepatoma, 2; melanoma, 1; and myeloma, 1) and 8 with benign disorder (dissecting aneurysm of the aorta, 6; chronic enteri-(FACS) lysing solution (Becton Dickinson) according to the manufacturer's instructions. Flow cytometric analysis was performed us-tis, 1; and chronic viral infection, 1) were studied. All of these patients were in the hypercoagulable state and were treated with ing a FACScan analyzer (Becton Dickinson) equipped with a 15-mW, 488-nm argon-ion laser. Green fluorescence emission was dilazep (300 mg/d) for 1 month before the initiation of any kind of therapy. Blood samples were collected from the patients before and recorded at 530 nm. A total of 10,000 events were analyzed per sample. Median channel fluorescence in each sample was determined after 1 month of starting the therapy with dilazep. Plasma levels of thrombin-antithrombin complex (TAT) and fibrin degradation prod-using a logarithmic scale. Logarithmic channel was converted into linear channel fluorescence units to facilitate comparison of results. uct (FDP)-D-dimer were determined using Enzygnost-TAT kit (Behringwerke AG, Marburg, Germany; normal range, 1.8 { 0.7 Measurement of total TF antigen level in HUVECs. The total cell TF antigen levels in lysates of HUVECs were measured by ng/mL 22 ) and Felisa D-dimer (Agen, Brisbane, Australia; normal range, 48 { 34 ng/mL 22 ), respectively. Plasma fibrinogen level was ELISA. 24 Briefly, after stimulation of HUVECs with TNF, thrombin, or PMA in the presence or absence of dilazep, the cells were washed determined using the clotting time method (normal range, 2.5 { 0.4 mg/mL 22 ) . The plasma level of TF antigen was determined by TF twice with cold Dulbecco's PBS and harvested. Subsequently, harvested cells were centrifuged (2,000 rpm for 5 minutes) and the enzyme-linked immunosorbent assay (ELISA) kit (Chemo-Sera Therapeutic Institute; normal range, 196.8 { 54.3 pg/mL). Data are precipitate was dissolved in Tris-buffered saline (TBS; 50 mmol/L Tris/HCl, 150 mmol/L NaCl, pH 7.5) containing, 0.6% (wt/vol) expressed as the mean { SD. The statistical difference between variables was evaluated by the Student's t-test or the Wilcoxon rank Triton X-100 and aprotinin (100 U/mL). The cellular extraction was then diluted 1,000-fold with TBS containing 0.1% BSA and 0.02% test according to the Gaussian distribution of the data.
Culture of HUVECs. HUVECs were purchased from Kurabo thimerosal and applied to wells coated with rabbit antihuman TF antibodies (American Diagnostica, Greenwich, CT). The wells were (Osaka, Japan). The cells were cultured in modified MCDB medium (Chlorella Industry, Tokyo, Japan) supplemented with 2% fetal bo-blocked with 100 mmol/L phosphate buffer, pH 8.0, containing 5% BSA, and then washed three times with TBS containing 0.1% BSA vine serum (GIBCO BRL, Grand Island, NY), 50 mg/mL gentamycin, 0.01 mg/mL epithelial growth factor (Becton Dickinson, Bed-and 0.02% thimerosal. Then, biotynyl-monoclonal antibody against human TF (MSTF-3) 23 was added and incubated for 2 hours. After ford, MA), 10 mg/mL endothelial cell growth factor (Becton Dickinson), and 10 mg/mL unfractionated heparin (Sigma) under an washing the wells, HRP-labeled streptavidin was added and incubated for 1 hour. After the addition of H 2 O 2 and peroxidase substrate, atmosphere of 95% air and 5% CO 2 .
Preparation of peripheral blood mononuclear cells. Peripheral color development was measured at 492 nm using an EAR microplate reader. blood cells were obtained from healthy donors by vein puncture using EDTA as anticoagulant. Mononuclear cells were isolated by Western blotting analysis of TF antigen in HUVECs. TF expression in HUVECs was determined by Western blotting using poly-the Lymphoprep Tube (Nycorned Pharma Diagnostica, Oslo, Norway). The mononuclear cell phase, comprising monocytes and lym-clonal goat antihuman TF antibodies (American Diagnostica). Sodium dodecyl sulphate-polyacrylamide gel electrophoresis of phocytes, was harvested, washed twice with RPMI (RPMI 1640 medium supplemented with 2 nmol/L L-glutamine, 100 mg/mL strep-HUVEC lysates was performed, followed by blotting onto nitrocellulose membrane. The membrane was incubated with blocking solution tomycin, 100 mg/mL penicillin, 10% fetal bovine serum), and resuspended in RPMI.
(100 mmol/L PBS, pH 7.5, containing 5% BSA and 0.5% Tween 20) and then exposed to a 1/2,000 dilution of goat anti-TF antibodies Determination of HUVEC surface TF activity. TF activity was determined as factor X activation by factor VIIa/TF complex on for 1 hour while shaking at room temperature. After washing the membrane with PBS containing 0.1% BSA and 0.5% Tween 20, the HUVECs after stimulation with TNF, thrombin, or PMA. After incubation of the cells (24-well plate, 5 1 10 5 cells/well) with each membrane was then incubated with a 1/20,000 dilution of antigoat IgG antibody conjugated to HRP. The membrane was washed and stimulant in the presence or absence of dilazep or adenosine, the cells were washed twice with HEPES-buffered saline (20 mmol/L quantitated using an enhanced chemiluminescence detection system (ECL; Amersham, Buckinghamshire, UK) as described previously. 25 HEPES, 150 mmol/L NaCl, pH 7.5) containing 5 mmol/L CaCl 2 . In separate experiments, 1 mmol/L 8-SPT was incubated with HU-Analysis of TF mRNA with reverse transcription and polymerase chain reaction (RT-PCR). Total RNA of HUVECs was prepared VECs for 15 minutes before the addition of dilazep. Aliquots of a mixture of 50 mL of 3.76 nmol/L factor VIIa, 50 mL of 980 nmol/L using the RNA zol (Cinna/Biotex Laboratories, Houston, TX) after stimulating the cells with TNF, thrombin, or PMA in the presence factor X, and 150 mL of HEPES-buffered saline containing 5 mmol/ L CaCl 2 were incubated in wells for 30 minutes at room temperature.
or absence of dilazep. RT-PCR was performed as described previously. 26, 27 Briefly, total RNA (1 mg) was reverse transcripted by The reaction was stopped by adding 10 mL of 100 mmol/L EDTA and the generated factor Xa was determined using 100 mmol/L S2222 superscript preamplification system (GIBCO BRL) with random AID Blood 0015 / 5h3d$$$281 08-12-97 13:29:26 blda WBS: Blood hexamer primers, and the reverse-transcripted cDNA was then am-reported previously. 29 Briefly, HUVECs were incubated with 100 mg/mL dilazep, followed by appropriate washing with cold Dulbec-plified by PCR using the primers prepared based on the mRNA of TF or GAPDH, a housekeeping gene 12 that was not affected by the co's PBS and harvesting of the cells. Subsequently, the cells were centrifuged (2,000 rpm for 5 minutes) and the precipitate was dis-stimulants used in this study. The sequences of the primers used for TF mRNA amplification were 5 ACTACTGTTTCAGTGTTC-solved in 50 mL TBS containing 0.6% (wt/vol) Triton X-100 and 0.2 U/mL aprotinin. The cell extract was then applied to the wells AAGCAGTGATTC 3 corresponding to 722-751 nucleotides and the 5 ATTCAGTGGGGAGTTCTCCTTCCCAGCTCTG 3 corre-coated with a monoclonal anti-TM IgG (MFTM-5). 29 The wells were blocked with PBS, pH 8.0, containing 5% BSA and then washed sponding to 925-954 nucleotides. 12, 28 The sequences of the primers used for GAPDH mRNA amplification were 5 CCACCCATGGCA-three times with TBS containing 0.1% BSA and 0.02% thimerosal. Thereafter, HRP-labeled monoclonal anti-TM IgG (MFTM-6) 29 was AATTCCATGGCA 3 corresponding to 150-169 nucleotides and 5 TCTAGACGGCAGGTCAGGTCCACC 3 corresponding to 720-added and incubated for 1 hour. After the addition of H 2 O 2 and peroxidase substrate, color development was measured at 492 nm 743 nucleotides. 12 PCR was performed with 22 cycles of 1 minute of denaturation at 94ЊC, 1 minute of hybridization at 52ЊC, and 2 using an EAR microplate reader. Determination of monocytic cell surface TF activity. Mononu-minutes of elongation at 73ЊC. An aliquot of sample was loaded onto a 2% agarose gel. Amplified DNA of TF or GAPDH was clear cells (monocytes plus lymphocytes) suspended in RPMI were incubated with or without 100 mg/mL dilazep for 15 minutes and blotted on a nylon membrane and hybridized with the TF or GAPDH cDNA probe labeled with a [ 32 P]dCTP (3,000 Ci/mmol) using a stimulated with TNF for 5 hours. Procoagulant activity (PCA) on the surface of intact monocytes was determined by a single-stage DNA labeling kit (TaKaRa Shuzo, Osaka, Japan). The membrane was then exposed to x-ray film at 070ЊC. The intensity of the hybrid-clotting assay as described previously. 30 Briefly, 50 mL of mononuclear cell suspension was mixed with 50 mL of 25 mmol/L CaCl 2 . ization signals was densitometrically quantified by a Fujix BAS-2000 Bio-Image analyzer (Fuji Photo Film, Tokyo, Japan). The amount of Clotting was initiated by the addition of 50 mL of normal human plasma, and the clotting time at 37ЊC was recorded using KC 10 TF mRNA was normalized against the GAPDH mRNA.
Determination of HUVEC surface thrombomodulin (TM) activity coagulometer (Heinrich Amelung, GmbH, Lemgo, Germany). The PCA was extrapolated from a standard curve drawn using rabbit and TM antigen in HUVECs. TM activity on the surface of HU-VECs was determined as a cofactor activity of TM for thrombin-brain thromboplastin standard (Ortho, Raritan, NJ), as described previously. 30 Cell surface-associated PCA was linear over the range catalyzed protein C activation using 48-well collagen-coated plates, as described previously. 29 After washing the HUVECs (2 1 10 5 of 12 1 10 6 mononuclear cells/mL. PCA of monocytes was confirmed to depend on TF, because it was specifically inhibited by cells) in the wells three times, 50 mL of TBS, pH 8.0, containing 0.1% BSA and 5 mmol/L CaCl 2 , 25 mL of 0.5 mg/mL thrombin, polyclonal anti-TF antibody. and 50 mL of 50 mg/mL protein C was added to each well. After 1 RESULTS hour of incubation at 37ЊC, antithrombin (5 mg/mL, final concentration) and heparin (2 U/mL, final concentration) were added to the These hemostatic parameters also decreased significantly in PMA on TF activity of HUVECs. TF activity on stimulated HUVECs for 5 hours depended on the dose of the stimulant each patient group (malignant and benign disease) after treatment with dilazep (P õ .001) as compared with baseline as described previously, 5-7 and the activity reached maximal levels at concentrations of 1,000 U/mL TNF, 25 nmol/L values (data not shown). This finding suggests that dilazep has a potent anticoagulant activity on endothelial cells or thrombin, and 5 nmol/L PMA, respectively. Coincubation with 100 mg/mL dilazep decreased approximately 90% of intravascular leukocytes. This preliminary clinical study prompted us to evaluate the effect of dilazep on endothelial the TF activity induced by each stimulant (Fig 3) . Increasing concentrations of dilazep (0 to 100 mg/mL) decreased the cell procoagulant activity.
Effect of dilazep on TF activity of HUVECs stimulated cell surface TF activity in a dose-dependent fashion (Fig 4) . The minimal concentration of dilazep required for inhibiting with TNF, thrombin, or PMA. We evaluated the effect of dilazep on TF expression in HUVECs stimulated with the the TNF-stimulated TF expression was 1 mg/mL, but that for the thrombin-and PMA-stimulated TF expression was inflammatory mediators TNF, thrombin, or PMA. A gradual increase in TF activity was observed on HUVECs after stim-0.1 mg/mL. The concentrations of dilazep required for 50% inhibition of the expression of TF activity on HUVECs in-ulating with TNF, thrombin, or PMA, reaching a maximum level after 5 to 6 hours. As shown in Fig 2, 100 mg/mL duced by 1,000 U/mL TNF, 25 nmol/L thrombin, and 5 nmol/L PMA were approximately 20, 2.5, and 20 mg/mL, dilazep inhibited this stimulatory effect of TNF, thrombin, or respectively. The viability of HUVECs as determined by analysis was also performed. TNF-stimulated HUVECs exhibited a prominent band with approximate molecular mass of 47 using WST-1 and 1-methoxy PMS was not affected by dilazep at any concentration used in this experiment.
kD, consistent with an increase in the mature form of TF. There was also an increase in a band at the 33-kD level. The addition To discern whether the inhibitory effect of dilazep on TF expression is caused by a global effect on protein synthesis, of dilazep to TNF stimulation prevented the increase in the high molecular mass band (47 kD) but caused an increase in the effect of dilazep on TM, which is constitutively expressed on resting HUVECs, was also investigated. The time the band at the 33-kD level (Fig 7) . Effect of dilazep on TF mRNA expression induced by TNF, course of the levels of TM activity and the total TM antigen expressed on HUVECs in the presence (100 mg/mL) or ab-thrombin, or PMA in HUVECs. To analyze whether the effect of dilazep on TF antigen levels in HUVECs (stimu-sence of dilazep were determined. The TM activity and the total TM antigen levels in the cells were not affected by lated with TNF, thrombin, or PMA) corresponds to the levels of TF mRNA in HUVECs, the effect of dilazep on the dilazep even after 24 hours of the treatment (data not shown).
Flow cytometry of TF antigen expression. FACScan steady-state levels of TF mRNA was assessed in HUVECs using the RT-PCR method. 27 Resting HUVECs and the cells analysis was performed to determine whether dilazep reduces the amount of TF antigen expression on HUVEC sur-treated with dilazep alone showed no detectable expression of TF mRNA ( Fig 8A) . As shown in Fig 8A and B, 1 ,000 face induced by TNF, thrombin, or PMA. As shown in Fig  5, dilazep alone did not affect the fluorescence intensity on U/mL TNF, 25 nmol/L thrombin, or 5 nmol/L PMA induced TF mRNA expression markedly after 3 hours of the treat-HUVECs, but markedly decreased the elevation of TF antigen levels on HUVECs induced by 1,000 U/mL TNF, 25 ment with each stimulant. Dilazep significantly inhibited the thrombin-or PMA-induced TF mRNA expression. However, nmol/L thrombin, or 5 nmol/L PMA.
Effect of dilazep on total TF antigen level in HUVECs the same amount of dilazep did not decrease the TF mRNA expression induced by TNF. These effects of dilazep on the stimulated with TNF, thrombin, or PMA. To investigate whether the suppressive effect of dilazep on HUVEC surface TF mRNA expression appear to correspond well to that on the total TF antigen level in HUVECs shown in Fig 6. 
TF activity depends on the decreased TF production by the cells, the total amount of TF antigen in HUVECs lysates
Effect of adenosine receptor antagonist on the inhibitory effect of dilazep. Dilazep is believed to potentiate the effect was measured by ELISA. Upregulation of total TF antigen level was observed in HUVECs treated with 1,000 U/mL of adenosine by blocking the uptake of adenosine. 31 In an attempt to clarify whether the inhibitory effect of dilazep on TNF, 25 nmol/L thrombin, and 5 nmol/L PMA. Dilazep (100 mg/mL) significantly inhibited the thrombin-and PMA-TF expression is mediated by adenosine receptor, the effect of the adenosine receptor antagonist, 8-SPT, on the inhibi-induced upregulation of total TF antigen levels ( 
Effect of adenosine on the TF activity of HUVECs stimu-
tope-technical studies using 3 H-dilazep in humans showed that the therapeutic concentration of dilazep in the systemic lated with TNF, thrombin, or PMA. Increasing concentrations of adenosine (0 to 10 mmol/L) decreased the TF activity circulation is around 1 mg/mL. 32 The therapeutical concentration of dilazep is known to increase the concentration of expression on the surface of HUVECs stimulated with 1,000 U/mL TNF, 25 nmol/L thrombin, or 5 nmol/L PMA in a adenosine in the extracellular space fluid up to micromolar levels. 33, 34 In our assays, we used a dose of dilazep equal dose-dependent fashion (Fig 10) . Coincubation with 10 mmol/L adenosine decreased approximately 50% the TF ac-to its therapeutic blood concentration in combination with adenosine. We found that dilazep, in combination with aden-tivity on HUVECs induced by each stimulant. These findings indicate that adenosine significantly blocks the TF expres-osine, inhibited the 1,000 U/mL TNF-and 25 nmol/L thrombin-induced TF expression in HUVECs more significantly sion in HUVECs stimulated with TNF, thrombin, or PMA. Viability of HUVECs as determined using WST-1 was not (60%) than dilazep alone, as shown in Fig 11. Effect of dilazep on TF activity of monocytes stimulated affected by adenosine at any concentration used in this experiment.
with TNF. Peripheral blood monocytes are known to participate in blood coagulation processes by expressing TF Additive effect of dilazep and adenosine on the TF activity of HUVECs stimulated with TNF, thrombin, or PMA. Iso-after being stimulated with inflammatory mediators. 35, 36 The AID Blood 0015 / 5h3d$$$281 08-12-97 13:29:26 blda WBS: Blood
For personal use only. on November 11, 2017. by guest www.bloodjournal.org From less than 0.1 mg/mL. Viability of mononuclear cells as determined by using WST-1 and 1-methoxy PMS was not affected by dilazep at any concentration used in this experiment.
DISCUSSION
Various cytokines, such as TNF, IL-1, and lymphotoxin, play relevant roles in several inflammatory processes and in the pathogenesis of atherosclerosis. Activation of endothelial cells by these mediators induces the expression of TF that converts the quiescent endothelium into a procoagulant surface. Increased thrombin generation at sites of vascular injury is believed to play a critical role in the pathogenesis of atherosclerosis. Antiplatelet therapy is commonly used in patients at risk of developing thrombotic disease. Dilazep is one of the antiplatelet drugs commonly used in European countries and Japan. Dilazep exerts antiplatelet activity by increasing the extracellular fluid level of adenosine in the systemic circulation by blocking adenosine uptake. 13, 14 Dilazep is also known to dilate coronary, cerebral, and renal vessels by blocking the calcium influx 15, 16 and to prevent the endothelial cell or leukocyte activation. 4,37 These findings prompted us to investigate the effect of dilazep on the procoagulant activity of HUVECs stimulated with TNF, thrombin, or PMA and on that of monocytes stimulated with TNF. The effect of dilazep on TNF-induced TF expression on monocyte surface was evaluated. Peripheral blood monocytes results of the present study showed that dilazep significantly inhibits the expression of TF in HUVECs and monocytes. were found to express 20.6 { 3.2 PCA U per 7 1 10 5 mononuclear cells. TNF (1,000 U/mL) increased 17.5-fold TF expression is known to be regulated at both transcriptional and posttranscriptional levels. 6, 25, 38, 39 In the current the monocyte TF activity (352.5 { 6.5 PCA U per 7 1 10 5 mononuclear cells). We then evaluated the effect of dilazep study, analysis of the TF mRNA expression showed that the thrombin-or PMA-induced TF expression in HUVECs is on TF expression by monocytes. Increasing the concentration of dilazep (0 to 100 mg/mL) inhibited the PCA of mono-blocked by dilazep probably due to an effect on TF gene transcription and/or TF mRNA stability. PMA and thrombin cytes in a dose-dependent fashion (Fig 12) . The concentration of dilazep required for inhibiting 50% of monocyte PCA are well-known activators of protein kinase C. This can be activated directly by PMA or indirectly by thrombin via was approximately 10 mg/mL. The minimal concentration of dilazep required for inhibiting the monocyte PCA was the G protein-coupled receptor. 40, 41 Thus, dilazep probably inhibits the PMA-or thrombin-induced TF mRNA expres-VECs. This latter finding may be explained by the different signaling pathway of TNF-induced TF expression from that sion by blocking the protein kinase C-mediated signaling pathway. On the contrary, dilazep inhibited the HUVEC of thrombin-or PMA-induced TF expression. In this regard, TNF was previously found to induce TF mRNA expression surface TF expression but it did not inhibit the expressions of total TF antigen and TF mRNA induced by TNF in HU-in HUVECs by the sphingomyelinase/ceramide pathway. 42 AID Blood 0015 / 5h3d$$$281 08-12-97 13:29:26 blda WBS: Blood In addition, TNF-mediated activation of protein kinase C is in general not required for nuclear factor-kB activation or for protein expression in endothelial cells. 43, 44 On the other hand, the fact that dilazep inhibited HUVEC surface expression of TF (decrease in TF activity and in its surface antigen expression by factor Xa generation assay and FACScan, respectively) without blocking the expression of total TF antigen and TF mRNA in these cells, as measured by ELISA and RT-PCR, suggests that dilazep regulates TNF-induced TF surface expression at the posttranscriptional level. Alternation in the folding, processing, and translocation of TF may be the potential mechanisms by which dilazep exerts this effect. Another piece of evidence that suggests the posttranscriptional regulation of TNF-induced TF expression by HUVECs is the results of the Western blot analysis showing For personal use only. on November 11, 2017. by guest www.bloodjournal.org From mg/mL. 32 On the other hand, the concentration of adenosine in the extracellular space fluid is known to increase up to micromolar levels in patients treated with dilazep. 33, 34 This effect depends on dilazep-induced inhibition of adenosine uptake by several cells. In our present investigation, at this reported blood therapeutic concentration, dilazep showed a modest degree of inhibitory activity on TF expression by HUVECs. However, the dose of dilazep equal to the therapeutic blood concentration of the drug in combination with adenosine significantly inhibited the expression of TF by HUVECs in our assay conditions. For instance, we found that dilazep in combination with adenosine inhibited the TNF-and thrombin-induced endothelial cell TF expression more significantly (60%) than dilazep alone. Based on these findings, we believed that, in biologic conditions (in the presence of adenosine), dilazep would inhibit significantly the TF expression by activated endothelial cells. Moreover, in the present study, dilazep was also found to inhibit the TNF-induced monocyte TF expression, supporting further the potential clinical usefulness of dilazep. Overall, these veno-occlusive diseases. 35, 36, 52, 53 Dilazep may have the potential to reduce the procoagulant activity of endothelial cells and monocytes observed in these disorders.
In summary, this study showed that dilazep inhibits endoby altering the stability and the translation rate of mRNA 45, 46 thelial TF expression at both transcriptional and posttranor by modifying protein folding or glycosylation. [47] [48] [49] [50] [51] The scriptional levels and that its inhibitory effect is mediated, antioxidant activity of dilazep might generate reduced condiat least in part, by adenosine receptors. The results of this tions in cytoplasm resulting in unstable/immatured forms of study also suggest that dilazep, besides its well-known anti-TF. Thus, it is conceivable that dilazep inhibits the transport platelet effect, exerts a potent inhibitory activity on the proof TF to the cell surface by affecting the formation of macoagulant activity of endothelial cells and monocytes. tured forms of the protein in TNF-stimulated HUVECs.
Another point that needs clarification is the mechanism REFERENCES by which dilazep activates the signaling pathway of HU-1. Nemerson Y: Tissue factor and hemostasis. Blood 71: 1, 1988 VECs for the transcriptional or posttranscriptional regulation 2. Miller CL, Graziano C, Lim RC, Chin M: Generation of tissue of TF. Dilazep was previously reported to inhibit adenosine factor by patient monocytes: Correlation to thromboembolic compliuptake by endothelial cells leading to increased plasma adencations. Thromb Haemost 46:489, 1981 osine levels. 31 In the current study, we evaluated whether Our present study showed that dilazep (300 mg/d) dramat- 
